Sildenafil Citrate Tablet
Product Images NDC 50090-3905

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 50090-3905). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 01)

A line graph illustrating the estimated cumulative mortality rate (%) over a period of 5 years, comparing three dosage groups: High dose, Medium dose, and Low dose. The y-axis represents mortality rates up to 25%, and the x-axis shows time in years. A table above the graph indicates the number of individuals at risk at various time points for each dose group.*

FDA Label Image

1 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 02)

Chemical structure diagram of Sildenafil Citrate, showing its molecular arrangement with labeled functional groups and atoms.*

FDA Label Image

7 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 03)

A scatter plot chart showing the fold change and 90% confidence intervals of drug interactions with Sildenafil Citrate compared to Sildenafil alone. It lists interacting drugs including Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir, indicating changes in AUC and Cmax values. Recommendations for dose adjustments are provided, with most drugs showing no dose adjustment needed except Ritonavir, where coadministration is not recommended.*

FDA Label Image

8 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 04)

A clinical interaction chart showing fold changes with 90% confidence intervals for pharmacokinetic parameters (AUC, Cmax, INR, BT) of sildenafil citrate when administered with various interacting drugs. The horizontal axis shows fold change relative to the interacting drug alone, ranging from 0.5 to 2. Recommendations about dose adjustments, generally indicating no adjustment needed, accompany each drug interaction.*

FDA Label Image

4 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 05)

A line graph showing change from baseline (in meters) over 12 weeks of study for placebo and sildenafil citrate at 20 mg, 40 mg, and 80 mg taken three times daily (TID). The x-axis represents weeks of study (Week 4, Week 8, Week 12) and the y-axis shows change from baseline. Data points include error bars, with sildenafil groups showing greater positive changes than placebo over time.*

FDA Label Image

5 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 06)

A forest plot showing placebo-corrected changes in 6-minute walk distance (meters) for Sildenafil 20 mg administered three times daily (TID) compared across various subgroups including baseline walk distance, pulmonary arterial hypertension (PAH) etiology, functional class, gender, age, mean pulmonary arterial pressure (PAP), and pulmonary vascular resistance index (PVRI). Each subgroup displays the number of patients in placebo and Sildenafil groups with corresponding point estimates and confidence intervals for the effect size.*

FDA Label Image

1 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 07)

Kaplan-Meier plot showing time in days to clinical worsening of PAS in Study 2. The graph depicts the percentage of participants without a clinically worsening event over time, comparing placebo and sildenafil groups from day 0 to 112 after randomization.*

FDA Label Image

Figure 12 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 08)

A line graph showing the mean change from baseline in six-minute walk distance (meters) over 12 weeks for three Sildenafil doses: 1 mg TID, 5 mg TID, and 20 mg TID. Data points with error bars indicate standard error at weeks 4, 8, and 12, illustrating improvement trends for each dose in a clinical study.*

FDA Label Image

9 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 09)

FDA Label Image

9 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 10)

FDA Label Image

Label Image (Lbl500903905)

SILDENAFIL CITRATE 20 mg oral tablets, packaged by A-S Medication Solutions. The label includes lot and product number, contains 30 tablets, and specifies storage at 68 to 77 degrees Fahrenheit. The label also references the equivalent amount of sildenafil and provides a QR code for dosage information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.